DHIVY
Peakcarbidopa levodopa
NDAORALTABLET
Approved
Nov 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
DHIVY (carbidopa levodopa) is dopa decarboxylase inhibitors [moa]. First approved in 2021.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DHIVY is an oral tablet formulation of carbidopa/levodopa, a combination dopamine precursor and decarboxylase inhibitor used to treat Parkinson's disease motor symptoms. Levodopa is converted to dopamine in the brain to restore neurotransmitter levels, while carbidopa blocks peripheral conversion to enhance CNS penetration. This is a foundational therapy for managing motor fluctuations and bradykinesia in Parkinson's patients.
$0.995MPart D
Peak12.4 years to LOEProduct is at peak lifecycle stage with stable Part D claims volume; commercial teams are focused on maximizing existing market penetration rather than expansion.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid Decarboxylation Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DHIVY offers stable, mature-market experience in a foundational Parkinson's therapy with no linked job postings, suggesting the position is either highly specialized or embedded in larger commercial teams. This is an ideal role for professionals seeking deep expertise in neurology and chronic disease management rather than high-growth launch dynamics.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.